Similar Items: Investigation of the molecular epidemiology of HIV-1 in Khayelitsha, Cape Town, using serotyping and genotyping techniques
- A comparative analysis of mathematical models for HIV epidemiology
- Characterisation of the HIV-1 subtype C Env gene and the expression of the Env protein from selected isolates in mammalian cells
- Optimisation and benchmarking of analytical approaches to estimation of population level HIV incidence from survey data
- Molecular characterisation of HIV-1 recombinants and non-subtype C viruses in South Africa
- Karakterisering van sekere aspekte van menslike immuungebrek virus tipe 1 (HIV-1) isolate
- Die gebruik van en behoefte aan sosiale ondersteuning onder huishoudings met gesinslede wat as MIV-positief gediagnoseer is
Author: Engelbrecht, Susan
- Origin and phylodynamics of HIV-1 subtype C in South Africa
- Molecular characterization of non-subtype C and recombinant HIV-1 viruses from Cape Town, South Africa
- Investigation of the molecular epidemiology of HIV-1 in Khayelitsha, Cape Town, using serotyping and genotyping techniques
- Mutagenesis and functional studies of the HIV-1 vpr gene and Vpr protein obtained from South African virus strains
- Phylogenetic analysis of HIV-1 in Mpumalanga
- Eienskappe van 'n selkultuurkontaminant
Author: Jacobs, Graeme Brendon
- Characterization of HIV-1 subtype B near full-length genome sequences identified at the start of HIV epidemic in South Africa
- Investigation of the molecular epidemiology of HIV-1 in Khayelitsha, Cape Town, using serotyping and genotyping techniques
- Investigating the structural impact of hiv-1 integrase natural occurring polymorphisms and novel mutations identified among group m subtypes circulating in sub-Saharan Africa
- Molecular characterisation of HIV-1 recombinants and non-subtype C viruses in South Africa
- HIV-1 molecular diversity and drug resistance mutations amongst immuno-competent, therapy naïve infants/children and adults in Yaounde, Cameroon
- Multidisciplinary viral analyses in people living with HIV-1C and receiving second-line combination antiretroviral therapy (cART) in South Africa